AZN’s Brilinta One note regarding the PLATO study: in the U.S patients subgroup, which was only about 10% of patients in the study, there was a 25% higher chance for CV event for those on Brilinta than for those on Plavix.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.